<DOC>
	<DOCNO>NCT00654732</DOCNO>
	<brief_summary>The goal clinical research study compare effectiveness receive Adriamycin ( doxorubicin hydrochloride ) , bleomycin , vinblastine , dacarbazine ( ABVD ) therapy alone receive ABVD rituximab .</brief_summary>
	<brief_title>Phase II R-ABVD Versus ABVD Advanced Stage Classical Hodgkin Lymphoma</brief_title>
	<detailed_description>The Study Drugs : ABVD combination chemotherapy drug make doxorubicin hydrochloride , bleomycin , vinblastine , dacarbazine . The combination drug design stop growth cancer cell , may cause cell die . Rituximab design attach cancer cell , may cause die . Study Groups : If eligible take part study , randomly assign ( like flip coin ) 1 2 treatment `` group '' . If Group 1 , receive ABVD rituximab . If Group 2 , receive ABVD . No matter group assign , dose drug standard dos currently use treat lymphoma . Group 1 : If assign Group 1 , receive ABVD combination needle vein 1 hour Day 1 15 every cycle ( every 2 week ) . Each cycle 4 week . You also receive rituximab vein 7 hour Days 1 , 8 ,15 22 ( week ) Cycle 1 . For Cycle 1 , enough time ABVD Rituximab give Day 1 , may receive Rituximab Day 2 . For Cycle 2 , receive rituximab Days 1 8 . You take rituximab first 2 cycle . Group 2 : If assign Group 2 , receive ABVD combination needle vein 1 hour Day 1 15 every cycle ( every 2 week ) . Each cycle 4 week . You receive rituximab . Study Visits : While study test procedure perform certain time study doctor think may necessary . The following test procedure perform : - On Day 1 15 cycle , blood ( 3-4 teaspoon ) draw routine test . - After every 4 dos ABVD , also chest x-ray CT scan neck , chest , abdomen , pelvis . - If first PET scan show lymphoma body , PET scan every 4 dos ABVD PET scan show lymphoma tumor body . Length Study : You remain study 6 cycle ( 23 week ) . You take study early disease get bad , start new treatment cancer , experience intolerable side effect . End-of-Treatment Visit : Before take study , end-of-study visit . The following test procedure perform : - You physical exam . - Your complete medical history record . - Blood ( 3-4 teaspoon ) draw routine test . - You also chest x-ray CT scan neck , chest , abdomen , pelvis check size location cancer . - If first PET scan show lymphoma body , PET scan . Follow-up Visits : After last study visit , return follow visit every 3 month Year 1 , every 4 month Year 2 , every 6 month Years 3-5 , year check status disease . At visit , follow test procedure perform : - You physical exam . - Your complete medical history record . - Blood ( 3-4 teaspoon ) draw routine test . - You also chest x-ray CT scan neck , chest , abdomen , pelvis check size location cancer . - If first PET scan show lymphoma body , PET scan . About 2 week last dose study drug ( ) , lymphoma cell first bone marrow aspiration biopsy , bone marrow aspiration biopsy check status disease . This investigational study . The ABVD combination FDA approve commercially available patient Hodgkin 's disease . Rituximab FDA approve commercially available . The combination ABVD rituximab consider investigational . Up 120 patient take part study . Up 70 enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Previously untreated patient classical Hodgkin 's lymphoma patient stage III IV . International Prognostic Score &gt; 2 ( patient must &gt; 2 follow risk feature : Male , &gt; /= 45 year age , Stage IV , Albumin &lt; 4 , White Blood Count ( WBC ) &gt; /= 15 , Lymphocytes &lt; 8 % &lt; 600 , Hgb &lt; 10.5 ) . Must sign consent form . Must old 16 year . Must adequate bone marrow reserve ( absolute neutrophil count ( ANC ) &gt; /= 1,500/microL , Platelet &gt; 100,000/microL ) . Left ventricular ejection fraction ( LVEF ) &gt; /= 50 % Multi Gated Acquisition Scan ( MUGA ) scan echocardiogram . Serum creatinine &lt; 2 mg/dl , serum bilirubin &lt; 2 mg/dl , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; 2 * ULN . Bidimensionally measurable disease . Lymphocyte Predominant Hodgkin 's Lymphoma . Known HIV infection . Pregnant woman woman child bear age practice adequate contraception . Prior chemotherapy radiation therapy . Severe pulmonary disease judge PI include chronic obstructive pulmonary disease ( COPD ) asthma . Active infection require treatment intravenous therapy . Presence central nervous system ( CNS ) lymphoma . Concomitant malignancies previous malignancy within last 5 year ( exception make adequately treated basal squamous cell carcinoma skin carcinoma situ cervix ) . Active hepatitis B C infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS®</keyword>
	<keyword>Adriamycin RDF™</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Bleomycin sulfate</keyword>
	<keyword>Blenoxane®</keyword>
	<keyword>BLM</keyword>
	<keyword>Vinblastine</keyword>
	<keyword>Velban</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>DTIC</keyword>
	<keyword>DTIC-Dome®</keyword>
	<keyword>R-ABVD</keyword>
	<keyword>ABVD</keyword>
</DOC>